News

Analysts upgrade Neurocrine Biosciences with mixed price target changes

Finance

Analysts upgrade Neurocrine Biosciences with mixed price target changes

12 sourcesUpdated Nov 11, 20261 min read

0

Analysts upgrade Neurocrine Biosciences with mixed price target changes — © IJR

Sponsored

Analysts have recently tilted more positive on Neurocrine Biosciences, with Wall Street Zen and Weiss Ratings upgrading the stock and several firms raising price targets, including Guggenheim, Canaccord Genuity and Piper Sandler. Views are not unanimous: Morgan Stanley maintained an equal-weight rating, while BMO Capital Markets cut its target and retained a market-perform rating. Institutional investors showed mixed activity in the third quarter, as Pictet Asset Management reduced its stake by 8.7% and the University of Texas/Texas A&M Investment Management Co. cut its holdings by 89.9%, while other funds increased their positions. Institutional investors collectively owned 92.59% of the company’s shares.

Sponsored

In this story:

More on this story

Back to News

Business

Rolls-Royce announces £1.5bn buyback, reaffirms 2026 guidance

Rolls-Royce announced an accelerated £1.5 billion share buyback, part of its existing £7 billion–£9 billion program, and reaffirmed its 2026 profit and free-cash-flow guidance. Strong engine demand has lifted its large-engine backlog to about 2,500, while flying hours and power-systems orders are also growing.

23 sources

Business

BAE Raises 2026 Cash-Flow Guidance 50% to £3B

9

Total sources12

Last updatedNov 11, 2026

Does this breakdown look right?

Sponsored

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

Coverage

Sponsored

Comments

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Sponsored

BAE Systems raised its annual free cash flow forecast about 50% to £3 billion, citing customer advances and strong demand as governments increase defense spending. It kept its sales and profit growth outlook unchanged, while reporting £33 billion in orders so far this year and anticipating further agreements before year-end.

7 sources

Sponsored

Business

Anthropic IPO Valuation Could Reach $1.5 Trillion

Anthropic’s planned IPO is facing mounting uncertainty as investors reportedly push to lower its expected valuation from roughly $1.4 trillion–$1.5 trillion, with estimates ranging toward $1 trillion to $1.3 trillion amid a sell-off in AI stocks. Prediction-market odds for a near-term listing have also fallen, and reports say the company could reduce the offering or delay it.

437 sources